A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease

Recruiting

Phase 3

EmicizumabA Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease

Sponsor:

Hoffmann-La Roche

Code:

NCT06998524

Conditions

Von Willebrand Disease, Type 3

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Interventions

Emicizumab

von Willebrand Factor (VWF) Concentrates

Factor VIII (FVIII) Concentrates

von Willebrand Factor (VWF) and Factor VIII (FVIII) Concentrates

Bypassing Agents

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-15. This information was provided to ClinicalTrials.gov by Hoffmann-La Roche on 2026-08-10.